Most reports on chronic myeloid leukaemia (CML) treatment with tyrosine kinase inhibitors
(TKIs) focus on efficacy, particularly on molecular response and outcome. In contrast …

Fibrosis is part of a tissue repair response to injury, defined as increased deposition of
extracellular matrix. In some instances, fibrosis is beneficial; however, in the majority of …

Although kinase inhibitors raise hope for people with cancer, patients and their clinicians are
commonly confronted with the cutaneous side-effects that are associated with the use of …

The introduction of imatinib, a specific inhibitor of the Bcr-Abl tyrosine kinase, has
dramatically changed the management of chronic myeloid leukemia (CML). More than …

Purpose A transgenic mouse model has revealed parameters of the angiogenic switch
during multistep tumorigenesis of pancreatic islets, and demonstrated efficacy of …

Abstract Learning Objectives After completing this course, the reader will be able to:
Describe the mechanism of action (ie, the molecular targets) of the anticancer drug imatinib …

Imatinib mesylate (IM), an original Abl tyrosine kinase inhibitor, entered the clinics in 1998
for the treatment of patients with chronic myeloid leukemia (CML). The drug is universally …

Although induction of apoptosis (cell death mediated by caspases) determines response to
cancer therapy, this approach is limited by lack of selectivity in available apoptosis-inducing …

Treatment options for chronic myeloid leukemia (CML) have changed dramatically during
the last decades. Interferon-α treatment and stem cell transplantation (SCT) clearly improved …

Whereas radioimmunotherapy of hematologic malignancies has evolved into a viable
treatment option, the responses of solid tumors to radioimmunotherapy are discouraging …